The US Food and Drug Administration (FDA) responded with a letter of no objection to Cargill’s GRAS (Generally Recognized As Safe) notification for EpiCor postbiotic use in certain foods and beverages.
EpiCor postbiotic is a dried yeast fermentate clinically shown in dietary supplement trials to beneficially modulate the gut microbiota and provide immune system support. A first-of-its-kind postbiotic widely used in popular supplements, the letter of no objection enables food and beverage manufacturers to incorporate EpiCor into a variety of foods and beverages.
Postbiotics are an emerging category in the immune and gut health space. Earlier this month, the International Scientific Association for Probiotics and Prebiotics (ISAPP) published a consensus statement on the definition and scope of postbiotics in the Nature Reviews Gastroenterology & Hepatology journal. This consensus definition states postbiotics are ‘a preparation of inanimate microorganisms and/or their components that confer health benefits on the host’.
EpiCor postbiotic is backed by extensive research in dietary supplements. Fifteen published studies, including eight human clinical trials, support EpiCor postbiotic’s health benefits related to both digestive and immune support.